(Boursier.com) — Pharnext SCA, an advanced clinical stage biopharmaceutical company developing new therapies for neurodegenerative diseases without satisfactory therapeutic solutions, announces today that the management of the Company, on the basis of the 9th resolution voted at the General Meeting of June 30 2023, has decided to carry out a capital reduction motivated by losses by reducing the par value of the company’s shares.
The par value of the share is reduced from 0.10 euros to 0.05 euros. The share capital of the Company, divided into 1,881,682 shares, was reduced from 188,168.20 euros to 94,084.10 euros.
©2024 Boursier.com